Get the Stockscreener App
1.20
2.44%
-0.03
After Hours:
1.19
-0.01
-0.83%
Novabay Pharmaceuticals Inc stock is traded at $1.20, with a volume of 218.54K.
It is down -2.44% in the last 24 hours and down -53.67% over the past month.
NovaBay Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets non-antibiotic and anti-infective products for the eye care market in the United States, China, and internationally. It offers Avenova, a prescription product for cleansing and removing foreign materials, including microorganisms and debris from skin around the eye; NeutroPhase for wound care market; CelleRx for the aesthetic dermatology market; Aganocide compounds patented synthetic molecules for use against bacteria, viruses, and fungi; auriclosene irrigation solution for urology; and intelli-Case, a device for soft and rigid gas permeable contact lenses. NovaBay Pharmaceuticals, Inc. has collaboration and license agreement with Virbac to develop auriclosene, a proprietary compound for veterinary markets. The company was formerly known as NovaCal Pharmaceuticals, Inc. and changed its name to NovaBay Pharmaceuticals, Inc. in February 2007. NovaBay Pharmaceuticals, Inc. was incorporated in 2000 and is based in Emeryville, California.
See More
Previous Close:
$1.23
Open:
$1.26
24h Volume:
218.54K
Relative Volume:
0.03
Market Cap:
$6.99M
Revenue:
$14.64M
Net Income/Loss:
$-13.74M
P/E Ratio:
-0.1651
EPS:
-7.27
Net Cash Flow:
$-5.04M
1W Performance:
-1.64%
1M Performance:
-53.67%
6M Performance:
+126.46%
1Y Performance:
+92.62%
1-Day Range:
$1.16
$1.275
1-Week Range:
$1.1525
$1.38
52-Week Range:
$0.46
$4.44
Novabay Pharmaceuticals Inc Stock (NBY) Company Profile
Name
Novabay Pharmaceuticals Inc
Sector
Industry
Phone
510-899-8800
Address
2000 Powell Street, Suite 1150, Emeryville, CA
Compare NBY with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NBY
Novabay Pharmaceuticals Inc
|
1.20 | 7.39M | 14.64M | -13.74M | -5.04M | -7.27 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.37 | 104.55B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
464.95 | 60.36B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
557.73 | 59.84B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
799.56 | 49.07B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
327.03 | 35.16B | 4.56B | -176.77M | 225.30M | -1.7177 |
Novabay Pharmaceuticals Inc Stock (NBY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-18-19 | Initiated | Ladenburg Thalmann | Buy |
| Jul-06-18 | Reiterated | H.C. Wainwright | Buy |
| Nov-15-17 | Reiterated | Laidlaw | Buy |
| Jun-05-17 | Initiated | ROTH Capital | Buy |
| Mar-27-17 | Initiated | Laidlaw | Buy |
| Feb-06-17 | Initiated | Rodman & Renshaw | Buy |
| Mar-07-16 | Downgrade | Maxim Group | Buy → Hold |
| Dec-14-15 | Reiterated | Maxim Group | Buy |
| Apr-30-15 | Resumed | Maxim Group | Buy |
| Mar-06-13 | Initiated | Ascendiant Capital Markets | Strong Buy |
| Jan-03-08 | Initiated | Dawson James | Speculative Buy |
View All
Novabay Pharmaceuticals Inc Stock (NBY) Latest News
NovaBay Pharmaceuticals Inc. stock trendline breakdownPortfolio Gains Summary & High Accuracy Trade Signal Alerts - newser.com
Is NovaBay Pharmaceuticals Inc. reversing from oversold territory2025 Fundamental Recap & AI Driven Stock Price Forecasts - newser.com
Statistical indicators supporting NovaBay Pharmaceuticals Inc.’s strengthPortfolio Growth Summary & Fast Gaining Stock Reports - newser.com
Institutional scanner results for NovaBay Pharmaceuticals Inc.July 2025 WrapUp & Advanced Swing Trade Entry Plans - newser.com
What technical signals suggest for NovaBay Pharmaceuticals Inc. stockTrade Risk Report & Risk Adjusted Buy and Sell Alerts - newser.com
Custom strategy builders for tracking NovaBay Pharmaceuticals Inc.Trade Exit Summary & Safe Entry Zone Identification - newser.com
Can NovaBay Pharmaceuticals Inc. (B9P0) stock beat analyst consensusQuarterly Growth Report & Technical Pattern Recognition Alerts - newser.com
Can NovaBay Pharmaceuticals Inc. stock hit analyst price targetsTrade Risk Assessment & Weekly Stock Performance Updates - newser.com
What institutional flow reveals about NovaBay Pharmaceuticals Inc.Market Sentiment Summary & Weekly Momentum Stock Picks - newser.com
NovaBay Pharmaceuticals CEO David Lazar to resign following stock transfer agreement - Investing.com Canada
Visual analytics tools that track NovaBay Pharmaceuticals Inc. performance2025 Geopolitical Influence & Community Consensus Trade Signals - newser.com
Published on: 2025-10-09 05:27:34 - newser.com
Using flow based indicators on NovaBay Pharmaceuticals Inc.Weekly Earnings Recap & Daily Risk Controlled Trade Plans - newser.com
Reviewing AngioSoma (OTCMKTS:SOAN) and NovaBay Pharmaceuticals (NYSEAMERICAN:NBY) - Defense World
NovaBay Pharmaceuticals Inc Stock Analysis and ForecastPrice Volatility Patterns & Budget Friendly Portfolio Growth - earlytimes.in
Why NovaBay Pharmaceuticals Inc. stock is popular among millennialsTrade Analysis Report & Verified Swing Trading Watchlists - newser.com
Will NovaBay Pharmaceuticals Inc. (B9P0) stock outperform small cap peersMarket Rally & Weekly Market Pulse Updates - newser.com
Is NovaBay Pharmaceuticals Inc. (B9P0) stock cheap by valuation metrics2025 AllTime Highs & Growth Focused Entry Reports - newser.com
How to read the order book for NovaBay Pharmaceuticals Inc.Weekly Volume Report & Weekly Market Pulse Updates - newser.com
What analysts say about NovaBay Pharmaceuticals Inc stockEarnings Miss Alerts & Low Cost Wealth Strategies - earlytimes.in
12 Health Care Stocks Moving In Monday's After-Market Session - Benzinga
How NovaBay Pharmaceuticals Inc. (B9P0) stock reacts to monetary easingQuarterly Trade Review & High Accuracy Trade Alerts - newser.com
Novabay Pharmaceuticals Inc Stock (NBY) Financials Data
Revenue
Net Income
Cash Flow
EPS
Novabay Pharmaceuticals Inc Stock (NBY) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| POPLAR POINT CAPITAL PARTNERS | 10% Owner |
Apr 04 '25 |
Buy |
0.52 |
4,538 |
2,367 |
1,020,000 |
| POPLAR POINT CAPITAL PARTNERS | 10% Owner |
Apr 02 '25 |
Buy |
0.58 |
917 |
532 |
992,486 |
| POPLAR POINT CAPITAL PARTNERS | 10% Owner |
Apr 08 '25 |
Buy |
0.47 |
300 |
140 |
1,020,300 |
| POPLAR POINT CAPITAL PARTNERS | 10% Owner |
Mar 28 '25 |
Buy |
0.61 |
49,400 |
30,253 |
950,000 |
| POPLAR POINT CAPITAL PARTNERS | 10% Owner |
Mar 31 '25 |
Buy |
0.59 |
21,654 |
12,776 |
971,654 |
| POPLAR POINT CAPITAL PARTNERS | 10% Owner |
Mar 27 '25 |
Buy |
0.61 |
19,104 |
11,745 |
900,600 |
| POPLAR POINT CAPITAL PARTNERS | 10% Owner |
Apr 01 '25 |
Buy |
0.58 |
19,915 |
11,650 |
991,569 |
| POPLAR POINT CAPITAL PARTNERS | 10% Owner |
Mar 26 '25 |
Buy |
0.61 |
13,292 |
8,095 |
881,496 |
| POPLAR POINT CAPITAL PARTNERS | 10% Owner |
Mar 25 '25 |
Buy |
0.61 |
22,635 |
13,807 |
868,204 |
| POPLAR POINT CAPITAL PARTNERS | 10% Owner |
Mar 18 '25 |
Buy |
0.63 |
14,000 |
8,820 |
832,277 |
1.11%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):